Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Inclusion Criteria: * Females must be of non-childbearing potential * Body mass index (BMI) ≥32.0 kg/m\^2 * In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests * No clinically significant abnormality on electrocardiogram * Has documented hepatic fat content ≥10% within 6 months of enrollment * Maintained stable weight (by history) for at least 4 weeks * Agrees not to initiate a weight loss program and agrees to maintain consistent dietary habits and exercise routines for the duration of the study * Has a rating of 'moderate' or 'severe' steatosis on ultrasound at the prestudy (screening) visit Exclusion Criteria: * Change in weight greater than 4% between prestudy visit and randomization into the study * History of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant * Liver disease other than fatty liver or non-alcoholic steatohepatitis (NASH) * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3x the upper limit of normal range * Serum triglyceride level \>600 mg/dL * History of stroke, chronic seizures, or major neurological disorder * History of clinically significant endocrine, gastrointestinal, cardiovascular (including congestive heart failure), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * Had abdominal surgery, gastric bypass, bowel resection, recent liver biopsy, or any other procedure within a minimum of 4 weeks * History of neoplastic disease * Claustrophobia or other contraindication to magnetic resonance imaging (MRI) * Have not washed off agents associated with changes in hepatic fat or used for treatment of Non-alcoholic fatty liver disease (NAFLD) or NASH for a minimum of 3 months prior * Consumes excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages * Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks * Significant multiple and/or severe allergies * Intolerance or hypersensitivity to pioglitazone hydrochloride or any inactive ingredients * Regular user of any illicit drugs or has a history of drug (including alcohol) abuse.